U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H14N8O4S3
Molecular Weight 454.511
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFAZOLIN

SMILES

Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@]([H])([C@@]3([H])SC2)N=C(Cn4cnnn4)O)s1

InChI

InChIKey=MLYYVTUWGNIJIB-BXKDBHETSA-N
InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H14N8O4S3
Molecular Weight 454.511
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cefazolin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. Cefazolin is used to treat bacterial infections of the skin, moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. This drug also can be used for perioperative prophylaxis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.18540796E11
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.18540796E11
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.18540796E11
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.18540796E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
280.9 μg/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
509.9 μg × h/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.01 h
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
healthy, 21 to 35 years
n = 7
Health Status: healthy
Age Group: 21 to 35 years
Sex: M
Population Size: 7
Sources:
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (14.3%)
Sources:
1.5 g 8 times / day multiple, intravenous
Highest studied dose
Dose: 1.5 g, 8 times / day
Route: intravenous
Route: multiple
Dose: 1.5 g, 8 times / day
Sources:
unhealthy, 21-34 years
n = 4
Health Status: unhealthy
Condition: endocarditis
Age Group: 21-34 years
Sex: M+F
Population Size: 4
Sources:
1 g 4 times / day multiple, intravenous
Recommended
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
healthy, 75 years
n = 1
Health Status: healthy
Age Group: 75 years
Sex: F
Population Size: 1
Sources:
Other AEs: Pseudomembranous colitis...
Other AEs:
Pseudomembranous colitis
Sources:
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy
n = 75
Health Status: unhealthy
Condition: closed fractures
Population Size: 75
Sources:
Other AEs: Infection...
Other AEs:
Infection (serious, 15 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Rash 14.3%
Disc. AE
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
healthy, 21 to 35 years
n = 7
Health Status: healthy
Age Group: 21 to 35 years
Sex: M
Population Size: 7
Sources:
Pseudomembranous colitis
1 g 4 times / day multiple, intravenous
Recommended
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
healthy, 75 years
n = 1
Health Status: healthy
Age Group: 75 years
Sex: F
Population Size: 1
Sources:
Infection serious, 15 patients
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy
n = 75
Health Status: unhealthy
Condition: closed fractures
Population Size: 75
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 1740 uM]
yes [Ki 180 uM]
yes [Ki 550 uM]
PubMed

PubMed

TitleDatePubMed
Double-blind comparison of phlebitis associated with cefazolin and cephalothin.
1976 Jul
Hemolysis induced by cefazolin and cephalothin in a patient with penicillin sensitivity.
1978 May-Jun
IgE antibodies for penicillins and cephalosporins in rats. III. Antigenic specificity of rat anti-cephalosporin-OvA IgE sera.
1981 Jan
Antigenicity of beta-lactam antibiotic preparations: production of IgE antibodies to beta-lactam antibiotic and their cross-reaction within the antibiotic group.
1982
Cephalosporin-induced cholestatic jaundice.
1982 Aug 7
Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer.
1983 Oct
[Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration].
1988 Jun
Pharmacological profile of the new anticonvulsant etazepine.
1989 Apr
Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins.
1990
Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources.
1990 Jul
Use of charge-transfer complexation in the spectrophotometric analysis of certain cephalosporins.
2001 Jul 6
Potassium permanganate-glyoxal chemiluminescence system for flow injection analysis of cephalosporin antibiotics: cefalexin, cefadroxil, and cefazolin sodium in pharmaceutical preparations.
2004 Sep 8
Radiographic and computed tomographic evaluation of experimentally induced lung aspiration sites in dogs.
2006 Dec
Attenuation of ischemia-reperfusion injury by ascorbic acid in the canine renal transplantation.
2006 Dec
Effects of ascorbic Acid, alpha-tocopherol and allopurinol on ischemia-reperfusion injury in rabbit skeletal muscle: an experimental study.
2007
Pro-convulsant effect of cefazolin sodium against pentylenetetrazol- or picrotoxin-induced convulsions in mice.
2007 Aug
[Simultaneous spectrophotometric determination of certain beta-lactam antibiotics in rabbit serum using multivariate calibration methods].
2007 Feb
Preclinical testing of the Levitronix Ultramag pediatric cardiac assist device in a lamb model.
2007 May-Jun
Conventional and dense gas techniques for the production of liposomes: a review.
2008
[Physical and chemical characteristics of a new cefazolin sodium hydrate crystal].
2008 Aug
Interaction of beta-lactam antibiotics with the mitochondrial carnitine/acylcarnitine transporter.
2008 Jun 17
An intractable case of Pseudomonas aeruginosa infection after scleral buckling for rhegmatogenous retinal detachment.
2008 Mar
How do porosity-inducing techniques affect antibiotic elution from bone cement? An in vitro comparison between hydrogen peroxide and a mechanical mixer.
2008 Mar
Treatment of sinusitis with corticosteroids in combination with antibiotics in experimentally induced rhinosinusitis.
2008 May
Cefazolin-induced hypoprothrombinemia.
2008 May 1
Trends in antibacterial use in US academic health centers: 2002 to 2006.
2008 Nov 10
[Retropharyngeal abscesses: a retrospective analysis of 10 patients].
2008 Sep-Oct
Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations.
2009
[Antibiotic susceptibility of pathogenic bacteria isolated from 893 children with lower respiratory infection in Guiyang].
2009 Dec
Functional recovery and neural differentiation after transplantation of allogenic adipose-derived stem cells in a canine model of acute spinal cord injury.
2009 Dec
Reactive astrocytes in glial scar attract olfactory ensheathing cells migration by secreted TNF-alpha in spinal cord lesion of rat.
2009 Dec 3
Kinetic spectrofluorimetric determination of certain cephalosporins in human plasma.
2009 Feb 15
The effects of methylprednisolone and cefazolin sodium on antioxidant status in experimentally induced maxillary sinusitis.
2009 Oct
Laser-induced silver nanoparticles on titanium oxide for photocatalytic degradation of methylene blue.
2009 Oct 29
Kinetic spectrophotometric determination of certain cephalosporins using oxidized quercetin reagent.
2009 Sep 1
Beneficial effect of the oxygen free radical scavenger amifostine (WR-2721) on spinal cord ischemia/reperfusion injury in rabbits.
2009 Sep 17
Ectopic intrauterine device in the bladder of a pregnant woman.
2010
Evaluating intra- and inter-examiner reproducibility in histometric measurement: one-wall intrabony periodontal defects in beagle dogs.
2010 Aug
Histological characteristics of newly formed cementum in surgically created one-wall intrabony defects in a canine model.
2010 Feb
Color selectivity of neurons in the posterior inferior temporal cortex of the macaque monkey.
2010 Jul
Acute osteomyelitis of the acetabulum induced by Staphylococcus capitis in a young athlete.
2010 Jun 18
Osteoid osteoma of the femur in a 7-month-old infant treated with radiofrequency ablation.
2010 Nov
Non-syndromic multiple supernumerary teeth in a family unit with a normal karyotype: case report.
2010 Nov 5
Periodontal regeneration capacity of equine particulate bone in canine alveolar bone defects.
2010 Oct
Investigation of the toxic functional group of cephalosporins by zebrafish embryo toxicity test.
2010 Oct
Sensitive chemiluminescence determination of thirteen cephalosporin antibiotics with luminol-copper(II) reaction.
2010 Oct
Stability of fortified cefazolin ophthalmic solutions prepared in artificial tears containing surfactant-based versus oxidant-based preservatives.
2010 Oct
Piezoelectric immunosensors for the detection of individual antibiotics and the total content of penicillin antibiotics in foodstuffs.
2014 Mar
Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity.
2015 Mar
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

Moderate to severe infections: 500 mg to 1 gram, every 6 to 8 hours; mild infections caused by susceptible gram-positive cocci: 250 mg to 500 mg, every 8 hours; acute, uncomplicated urinary tract infections: 1 gram, every 12 hours; Pneumococcal pneumonia: 500 mg, every 12 hours; Severe, life threatening infections (e.g., endocarditis, septicemia): 1 gram to 1.5 grams, every 6 hours
Route of Administration: Other
In Vitro Use Guide
Susceptibilities of 259 isolates of pathogenic bacteria to cefazolin were measured by broth and agar dilution procedures. Beta-hemolytic streptococci were inhibited by 0.25 mug/ml, whereas Staphylococcus aureus and alphahemolytic streptococci were inhibited by 2.0 mug/ml. Enterococci were resistant to less than 32 mug/ml. Wide variation was seen with gram-negative species. Most isolates of Klebsiella species and Proteus mirabilis were inhibited by 4.0 or 8.0 mug/ml. Escherichia coli were less susceptible, and most isolates of Pseudomonas aeruginosa, Serratia species, and Enterobacter species were resistant to 128 mug/ml.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:44 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:44 UTC 2021
Record UNII
IHS69L0Y4T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFAZOLIN
HSDB   INN   MART.   MI   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
CEFAZOLIN [MI]
Common Name English
CEFAZOLIN [INN]
Common Name English
CEFAZOLIN [USP MONOGRAPH]
Common Name English
CEFAZOLIN [WHO-DD]
Common Name English
(6R,7R)-3-(((5-METHYL-1,3,4-THIADIAZOL-2-YL)THIO)METHYL)-8-OXO-7-(2-(1H-TETRAZOL-1-YL)ACETAMIDO)5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-(((5-METHYL-1,3,4-THIADIAZOL-2-YL)THIO)METHYL)-8-OXO-7-(((1H-TETRAZOL-1-YL)ACETYL)AMINO)-(6R-TRANS)
Common Name English
J01DB04
Code English
CEFAZOLIN [VANDF]
Common Name English
CEFAZOLIN [HSDB]
Common Name English
CEFAZOLIN [MART.]
Common Name English
CEFAZOLIN [USP-RS]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
WHO-ATC J01DB04
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NCI_THESAURUS C357
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000175488
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
LIVERTOX 160
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
WHO-VATC QJ51DB04
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
NDF-RT N0000011161
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
WHO-VATC QJ01DB04
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
Code System Code Type Description
DRUG CENTRAL
530
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
ChEMBL
CHEMBL1435
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
NCI_THESAURUS
C28913
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
WIKIPEDIA
CEFAZOLIN
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
PUBCHEM
33255
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
LACTMED
Cefazolin
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
RXCUI
2180
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY RxNorm
MESH
D002437
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
ECHA (EC/EINECS)
247-362-8
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
EPA CompTox
25953-19-9
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
CAS
25953-19-9
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
USP_CATALOG
1097603
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY USP-RS
EVMPD
SUB07379MIG
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
DRUG BANK
DB01327
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
INN
2991
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
MERCK INDEX
M3188
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY Merck Index
HSDB
3213
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
FDA UNII
IHS69L0Y4T
Created by admin on Fri Jun 25 20:55:44 UTC 2021 , Edited by admin on Fri Jun 25 20:55:44 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC